Work

Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.5060

Authors: Vincenza Conteduca, Daniel Wetterskog, Mansour Taghavi Azar Sharabiani, Anuradha Jayaram, Samanta Salvi, Alessandro Romanel, Cristian Lolli, Valentina Casadio, Giorgia Gurioli, Dino Amadori, Delila Gasi Tandefelt, Anna Wingate, David P. Dearnaley, Francesca Demichelis, Ugo De Giorgi, Enrique González-Billalabeitia, Gerhardt Attard

Institutions: Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, St. James's Hospital, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Trento, Hospital General Universitario Morales Meseguer

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891172947

Cites:

Cited by: 1

Related to: 10